Catalyst Wire Dossier Catalyst Wire Dossier

Anti-Spike SARS-CoV-2 monoclonal antibodies

null · Regeneron Pharmaceuticals
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Anti-Spike SARS-CoV-2 monoclonal antibodies, covering 2022-07-25 to 2022-07-25. Get the full timeline:

Most recent: Clinical Trial Update: Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19 [Phase 1, Phase 2]

See pricing